We corroborated in cSCC patient samples that the frequency of GzmB+ cells decreased and the frequencies of CD8+PD-1+, CD8+LAG-3+, CD8+TIM-3+ and CD8+TIGIT+ cells increased in mixed and mesenchymal patient cSCCs (Supplementary Fig. 4a–j), which are those tumors enriched in hybrid E/M and mesenchymal cancer cells (Fig. 1k). This evidence concerns the gene GZMB and cancer.